The Milbank Memorial Fund is an endowed operating foundation that publishes The Milbank Quarterly, commissions projects, and convenes state health policy decision makers on issues they identify as important to population health.
We focus on a number of topic areas identified by state health policy leaders as important to population health.
The Center for Evidence-based Policy at Oregon Health & Science University is a national leader in evidence-based decision making and policy design.
Keep up with news and updates from the Milbank Memorial Fund. Get the latest from thought leaders, including Christopher F. Koller, president of the Fund.
We publish The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to population health.
News and Updates
June 24, 2016
As the end of the month approaches, so does the end of phase one of SMART-D, the State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs. A project of the Center for Evidence-based Policy (CEbP) at Oregon Health and Science University, SMART-D is part of a series of grants from the Laura and John Arnold Foundation in Houston, Texas, that address the rising cost of pharmaceutical drugs. The Center is a strategic partner of the Milbank Memorial Fund (MMF); the two organizations collaborate on promoting the development of evidence-informed health policymaking capacity in states.
SMART-D is aimed at developing a better menu of options for states to consider in purchasing high-cost drugs in Medicaid. Phase one of SMART-D concentrated on research, in which investigators looked at the current status of state Medicaid programs and high-cost drugs, including the options they have for paying for them. Researchers looked at four specific areas:
Before it is finalized, the work of phase one will be reviewed by an expert advisory panel convened by the MMF on behalf of the CEbP.
Phase two of the project will focus on planning—and help Medicaid programs identify potential collaborative agreements with drug manufacturers, focusing on patient outcomes and value-based reimbursements.
“States have a limited toolset in dealing with high-cost drugs,” says Pam Curtis, executive director of the CEbP. “Our work is focused on broadening the purchasing and cost management tools available to state Medicaid programs to ensure patient access to effective drugs that will improve health outcomes.” The goal of the project will be to pilot the alternative payment models between state Medicaid programs and drug manufacturers.
The Milbank Memorial Fund is an endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience.
Maine’s Family Caregiving Referendum—Revolt of the Sandwiched?
October 30, 2018
Provider Payment Reform: Right Course, Wrong Students?
September 24, 2018
When Things Go Wrong: Accountability and the Flint Water Crisis
August 28, 2018